Clinical Trials Logo

Clinical Trial Summary

It is a single blind randomized symptom triggered study to assess efficacy and safety of pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs. clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.


Clinical Trial Description

Study design: Single-blind randomized symptom-regulated protocol with an active control. Eighty patients admitted to an inpatient addiction treatment program will be randomly assigned to two groups. The first group (N=40) receives up to 600 mg a day of Pregabalin for six days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine). The second group (N= 40) receives up to 600 micrograms of Clonidine a day as the main treatment along with the same basic and symptomatic regimen. Opiate withdrawal severity, craving, sleep disturbance, anxiety and depression, as well as general clinical impressions and side effects are assessed daily by psychiatrists who are blind to patients' group assignment using internationally validated quantitative psychometric instruments. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03017430
Study type Interventional
Source St. Petersburg Bekhterev Research Psychoneurological Institute
Contact
Status Completed
Phase Phase 4
Start date January 2014
Completion date December 2019

See also
  Status Clinical Trial Phase
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Completed NCT04126083 - Lofexidine for Adults Undergoing Lumbar Spine Surgery Phase 4
Completed NCT04140955 - Opioid Tapering After Spine Surgery N/A
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Completed NCT01262092 - Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals Phase 2
Completed NCT04075214 - Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal N/A
Recruiting NCT04325659 - An Innovative Intervention for OUD Treatment Phase 2/Phase 3
Withdrawn NCT03678792 - Comparison of Three Opioid Detoxification Treatment Regimens Phase 3
Terminated NCT04162145 - BRIDGE Device for Treatment of Opioid Withdrawal N/A
Completed NCT04238754 - Oral Cannabidiol for Opioid Withdrawal Phase 1/Phase 2
Recruiting NCT05053503 - Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder N/A
Recruiting NCT05555485 - Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain N/A
Active, not recruiting NCT03485430 - Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up N/A
Recruiting NCT05790551 - Suboxone Dispenser for OUD N/A
Completed NCT03174067 - Buprenorphine in the Emergency Department Phase 4
Completed NCT04731935 - Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal N/A
Completed NCT04470050 - Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Phase 1/Phase 2
Not yet recruiting NCT06442566 - ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain Phase 1/Phase 2
Recruiting NCT05307458 - Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
Completed NCT03789214 - Medical Management of Sleep Disturbance During Opioid Tapering Phase 2